Rovensa Group Launches Rovensa Next, a New Global Biosolutions Business Unit to Shape a Sustainable Future for Agriculture
Faced with global challenges due to a growing population and climate change, among others, farmers need a solution to feed the planet through healthy and safe solutions. Today, Rovensa Group, a global leader of agricultural inputs for sustainable agriculture, answers that need with Rovensa Next, a new global business unit dedicated to biosolutions for agriculture that aims to give back to the Earth what the Earth gives to us. Rovensa Next makes its debut this week at Fruit Logistica Berlin (Hall 1.2, Stand B-50), the leading trade fair for the fresh fruit industry.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230208005486/en/
José Alfredo García, Co-COO Rovensa Next, Javier Calleja, incoming CEO Rovensa Group, Eric van Innis, CEO Rovensa Group and Carlos Ledó, Co-COO Rovensa Next (Photo: Business Wire)
Rovensa Next aggregates ten Rovensa Group companies, creating a holistic platform of innovative biosolutions to shape a sustainable future for agriculture and drive its bio-transformation. With this announcement, Agrichembio, Agrotecnología, Idai Nature, Microquimica, MIP Agro, OGT, Oro Agri, Rodel, SDP, and Tradecorp will become part of the new business unit, combining local technical knowledge, innovation and teams that work alongside farmers and distributors in the field to solve their sustainability challenges, with the global expertise and leadership of Rovensa Group.
Eric van Innis, Rovensa Group CEO, stated: “With this flagship project Rovensa Next, and our holistic platform of biosolutions, we are taking a strategic step forward in our goal to be a reference provider of well-balanced and sustainable solutions for agriculture. Farmers and distributors do not need a singular product or a multi-card generalist; they need specialised advisors to help them create a potent strategy that considers their local environment and challenges. Rovensa Next is our answer to our partners’ needs for sustainable crop management that leads to safe and healthy products with better quality and increased yield.”
Betting on sustainability, innovation, and technical expertise, Rovensa Next unites a global network of 30 R&D laboratories, excellence centres, fields, and greenhouses; 14 production plants; more than 84 partnerships with research centres and universities; 100 R&D and innovation specialists; and a dedicated team of more than 850 field expertsi. All of this allows Rovensa Next to be the pioneer on cutting-edge research to create more effective and environmentally friendly biosolutions that don’t compromise on performance or quality.
Carlos Ledó, Co-Chief Operating Officer of Rovensa Next, commented: “With a rising population and a rapidly changing climate, there is a clear need to transform the agricultural sector. The formation of Rovensa Next, consisting of ten brands with entrepreneurship in their DNA, gives us the right talent, know-how, expertise, and innovation to drive the necessary change in agriculture. The time is now for sustainable transformation.”
José Alfredo García, Co-Chief Operating Officer of Rovensa Next, added: “We want to be a trusted partner that helps our customers drive sustainable transformation without compromising on performance and yield output. Our unique value add is our team of field experts that work on the ground with growers to understand their needs and solve their challenges. By uniting all of our local and specialised expertise in various crops and geographical areas into one global portfolio of solutions, we aim to help facilitate, or even kickstart, the bio-transformation for customers, ultimately helping to shape an overall more sustainable future.”
With the new business unit, Rovensa Group anticipates a turnover of more than EUR 1 billion by 2025i. Today’s announcement marks the beginning of the global transition to Rovensa Next followed by local implementation across all countries from July 2023.
For more information, go to www.rovensanext.com
About Rovensa Group
Rovensa Group is a global leader in agricultural solutions for sustainable agriculture. It is a group of companies that develop, manufacture, and commercialise agricultural solutions to help farmers produce safe, healthy and nutritious food for all.
Committed to generating a positive impact through its companies, more than 4,000 employees strive each day to contribute to our mission of feeding the planet. With more than 30 Research and Development (R&D) experimental centres and laboratories across the world, we are leading the change in agriculture through science-led innovation to continuously develop pioneering agricultural inputs to preserve and enhance soil, environmental, and human health. We are providing farmers, spread over 80 countries across the globe, a complementary portfolio of solutions for bionutrition, biocontrol and crop protection to support the transition towards a more well-balanced agriculture, enabling them to grow a larger quantity and higher quality of food with fewer natural resources.
For more information, go to www.rovensa.com
- Rovensa Next figures including ten aggregated companies and the Cosmocel acquisition.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230208005486/en/
Contact information
For further information:
Rovensa Next
Elisa Lipperheide
Global Communication Manager
elisa.lipperheide@rovensanext.com
m. +34 687 111 148
Chelsey Rodowicz
Ogilvy PR
chelsey.rodowicz@ogilvy.com
m. +34 620 035 403
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
REGiMMUNE Limited Licenses the Rights to Develop and Commercialize RGI-2001 To San Fu Biotech in Major Asian Countries1.4.2023 19:18:00 EEST | Press release
REGiMMUNE Limited (REGiMMUNE), a biotech company focused on creating innovative immunotherapies for immune disorders and cancer, and San Fu Biotech (SFB), a subsidiary of San Fu Chemical Co., Ltd. (4755.TW) have entered a licensing agreement to develop and commercialize RGI-2001 for the prophylaxis of acute Graft-versus-host disease (aGvHD) in major Asian countries. RGI-2001, with the novel mechanism to improve existing treatments, is a potentially first-in-class small molecule drug candidate targeted for preventing aGvHD, a life-threatening complication resulting from allogeneic hematopoietic stem cell transplantation (HSCT). GvHD is a systemic disorder that occurs when the graft's immune cells recognize the host as foreign and attack the recipient’s body cells or organs, and leads to skin rash, liver problems, abdominal pain or cramps, diarrhea, and increased risk for infections. Patients undergoing allogeneic HSCT have a high-risk of developing aGVHD associated with significant morb
AriBio Co., Ltd. to Present Biomarker Data for AR1001 from the Mild to Moderate Alzheimer’s Disease Phase 2 Study at the International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders (AD/PD™ 2023)31.3.2023 19:00:00 EEST | Press release
AriBio Co., Ltd. announced that David Greeley MD, Chief Medical Officer at AriBio, will present biomarker data from the completed phase 2 study in patients with mild to moderate Alzheimer’s disease who were treated with 10mg and 30mg of AR1001. AR1001 is a potent PDE5 inhibitor with preliminary efficacy in cognition, and preclinical effects on neuron apoptosis inhibition, promotion of neurogenesis, increase in neuroplasticity, and stimulation of autophagy to remove toxic proteins. The phase 2 study was a double-blind, randomized, placebo-controlled, multi-center trial to evaluate the safety and preliminary efficacy of AR1001 over 26 and 52 weeks of treatment in patients with mild to moderate Alzheimer’s disease. The trial enrolled 210 patients at 21 research centers in the United States. Plasma collected from patients at baseline, week 26 and week 52 was analyzed by Quantarix using the Simoa HD-X analyzer. Meaningful, statistically significant changes were found over 52 weeks of treatm
KANEKA: “Development of Polymer Synthesis Technology by Microorganisms using CO2 as Direct Raw Material” selected as a NEDO Green Innovation Fund Project”31.3.2023 17:09:00 EEST | Press release
Kaneka Corporation (Headquarters: Minato-ku, Tokyo; President: Minoru Tanaka; hereinafter "Kaneka"), Bacchus Bio innovation Co., Ltd (Headquarters: Kobe-city, Hyogo; President: Mikio Tanji; hereinafter "Bacchus"), JGC Holdings Corporation (Headquarters: Yokohama-city Kanagawa; Chairman and CEO: Masayuki Sato; hereinafter "JGC HD"), and Shimadzu Corporation (Headquarters: Kyoto-city, Kyoto; President: Yasunori Yamamoto; hereinafter "Shimadzu") have announced that the proposal of a joint project, “Development of Polymer Synthesis Technology by microorganisms using CO2 as direct raw material (hereinafter referred to as ‘the Project’)” had been selected by the "Green Innovation Fund Project*1 / Promotion of Carbon Recycling Using CO2 from Biomanufacturing Technology as a Direct Raw Material” as a planned implementation sponsored by the New Energy and Industrial Technology Development Organization (NEDO). This press release features multimedia. View the full release here: https://www.busine
Allianz Appoints Leadership for Allianz Commercial Key Markets31.3.2023 16:11:00 EEST | Press release
As part of the implementation of its ‘Integrated Commercial’ strategy to better serve the full Commercial segment, Allianz Group today announced the leadership for four of its largest Property and Casualty Commercial insurance markets: Australia, France, Germany and the United Kingdom. In each country, the appointed single Commercial lead will represent the integrated Allianz Commercial business and bring to the market Allianz’s full set of solutions for specialty clients, large corporates, and mid-sized companies, simplifying and enhancing the experience of clients and distribution partners. “The appointment of the regional leaders in our core Allianz Commercial markets is an important, concrete step toward realizing our new integrated model, which brings together our Mid Corporate and Large Corporate insurance business for the benefit of our clients and distribution partners,” said Chris Townsend, Member of the Allianz SE Board of Management. Townsend added, “As one face to the marke
Huawei Releases 2022 Annual Report: Steady Operations, Sustainable Survival and Development31.3.2023 12:59:00 EEST | Press release
Huawei released its 2022 Annual Report today. The company reports steady operations throughout 2022, having generated CNY642.3 billion in revenue and CNY35.6 billion in net profits. Huawei continues to strengthen investment in R&D, with an annual expenditure of CNY161.5 billion in 2022, representing 25.1% of the company's annual revenue and bringing its total R&D expenditure over the past 10 years to more than CNY977.3 billion. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230331005166/en/ (Photo: Huawei) "In 2022, a challenging external environment and non-market factors continued to take a toll on Huawei's operations", said Eric Xu, Huawei's Rotating Chairman, at the company's annual report press conference. "In the midst of this storm, we kept racing ahead, doing everything in our power to maintain business continuity and serve our customers. We also went to great lengths to grow the harvest – generating a steady stream
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom